Abstract: Snakebite envenomation is a significant but vastly neglected public health problem, affecting mainly rural and low-income populations in sub-Saharan Africa, South Asia, and Central and South America. It causes significant mortality and long-term morbidity, including disabilities and psychological trauma. Conventional antivenoms, produced in animal plasma, have proven themselves to be essential tools in the management of systemic effects of venom; however, there are certain disadvantages, like delayed administration, risks of hypersensitivity reactions, and relatively poor efficacy in managing local tissue damage caused by cytotoxic venom components, such as PLA2, SVMPs, and 3FTx. In recent years, the molecular mechanisms of venom-induced tissue damage have been identified, allowing for the development of new treatments. Rapid neutralization of the enzyme is also possible with small-molecule inhibitors, such as varespladib, while monoclonal antibodies and synthetic nanoparticles offer hope for targeted and broad-spectrum therapies. New technologies to treat snakebites, such as oligoclonal antibody mixtures, such as 95Mat5, which targets elapid neurotoxins, and de novo-designed proteins, have emerged with great promise. Furthermore, plant-derived compounds from Crataeva nurvala, Mucuna pruriens, and Eclipta prostrata have demonstrated venom-inhibiting activities in experiments, including the inhibition of tissue damage, prevention of blood clotting, and inactivation of toxins. However, these plant-based treatments have not yet been validated in large-scale human clinical trials. Although some plants show potential as antivenoms, their actual efficacy in real-life snakebite cases remains largely untested. Additionally, natural inhibitors found in both plants and animals remain relatively unexplored. This perspective discusses the challenges associated with traditional antivenoms and how novel therapies can revolutionize the treatment of snakebites, making them safer, more accessible, and more effective, thereby reducing the global burden of snakebite.
Hussain et al. (Tue,) studied this question.